Introduction: Chronic allograft vasculopathy (CAV) is a major limiting factor of long-term allograft survival. Although some mechanisms involved in CAV have already been identified, there is no specific treatment for this clinical condition. Considering the immune-inflammatory events involved in the development of CAV, therapeutic approaches to target this process are of relevance. In this context, human amniotic fluid derived stem cells (hAFSC), a class of fetal, pluripotent stem cells with intermediate characteristics between embryonic and adult stem cells, may represent an alternative strategy. hAFSC display immunomodulatory properties, express mesenchymal and embryonic markers, show high proliferation rates, but do not induce tumor formation and their use does not raise ethical issues. Based on these observations, we sought to investigate the effect of hAFSC on CAV in a model of aorta transplantation. Methods: Experimental aorta transplantation was performed using Fisher (F344) rats as donors and Lewis rats as recipients. The abdominal aorta segment, obtained from the emergency of renal arteries until its bifurcation, was orthotopically anastomosed in syngeneic or allogeneic recipients. hAFSC were isolated from amniotic fluid of 16-20 weeks pregnant women, who underwent amniocentesis due to advanced maternal age. Briefly, these cells were cultivated in Dulbecco's modified Eagle's medium-low glucose (DMEM-low) supplemented with 10% fetal bovine serum. hAFSC were purified using their characteristic to adhere to plastic culture dishes, characterized by flow cytometry, and characterized by their potential osteogenic, adipogenic, and chondrogenic differentiation. In addition, RT-PCR experiments demonstrated that these hAFSC express OCT-4 4/5 and NANOG. Rats were divided into 3 groups: syngeneic (SYNG), untreated F344 receiving syngeneic aorta from F344 (n=8); allogeneic (ALLO), Lewis rats receiving allogeneic aorta from F344 (n=8); and ALLO+hAFSC, ALLO rats treated with hAFSC (106 cells) (n=8). Histological analysis and immunohistochemistry were performed 30 days post transplantation. Results: Neointima formation was not observed in the SYNG group. However, the intimal thickness was dramatically increased in the ALLO group accompanied by a high number of ED1+ and CD43+ cells, and enhanced expression of α-SMA in the neointima. Treatment with hAFSC attenuated neointimal thickness and induced a significant decrease of ED1+, CD43+ cells as well as α-SMA expression in the neointima. Table 1: Effects of hAFSC in experimental aortic allograft vasculopathy.Table: No Caption available.Conclusion: These preliminary results showed that hAFSC suppressed inflammation and myofibroblast migration in the intima, possibly through immunomodulatory properties, which may have contributed to ameliorate vascular lesions in CAV.